ZNF507 affects TGF-β signaling via TGFBR1 and MAP3K8 activation in the progression of prostate cancer to an aggressive state

Wookbong Kwon 1,2†, Seong-Kyoon Choi 1,2‡*, Daehwan Kim 1,2,3, Hyeon-Gyeom Kim 1, Jin-Kyu Park 4, Jee Eun Han 4, Gil-Jae Cho 4, Sungho Yun 4, Wookyung Yu 5, Se-Hyeon Han 6,7, Yun-Sok Ha 8, Jun Nyung Lee 8, Tae Gyun Kwon 8, Dong-Hyung Cho 3,9, Jun-Koo Yi 10, Myoung Ok Kim 11, Zae Young Ryoo 3* and Song Park 1,5*

Abstract

Background: The progression of prostate cancer (PC) to the highly aggressive metastatic castration-resistant prostate cancer (mCRPC) or neuroendocrine prostate cancer (NEPC) is a fatal condition and the underlying molecular mechanisms are poorly understood. Here, we identified the novel transcriptional factor ZNF507 as a key mediator in the progression of PC to an aggressive state.

Methods: We analyzed ZNF507 expression in the data from various human PC database and high-grade PC patient samples. By establishment of ZNF507 knockdown and overexpression human PC cell lines, we assessed in vitro PC phenotype changes including cell proliferation, survival, migration and invasion. By performing microarray with ZNF507 knockdown PC cells, we profiled the gene clusters affected by ZNF507 knockdown. Moreover, ZNF507 regulated key signal was evaluated by dual-luciferase reporter and chromatin immunoprecipitation (ChIP) assays. Finally, we performed xenograft and in vivo metastasis assay to confirm the effect of ZNF507 knockdown in PC cells.

Results: We found that ZNF507 expression was increased, particularly in the highly graded PC. ZNF507 was also found to be associated with metastatic PC of a high grade. Loss- or gain-of-function–based analysis revealed that ZNF507 promotes the growth, survival, proliferation, and metastatic properties of PC (e.g., epithelial-mesenchymal transition) by upregulating TGF-β signaling. Profiling of gene clusters affected by ZNF507 knockdown revealed that ZNF507 positively regulated the transcription of TGFBR1, MAP3K8, and FURIN, which in turn promoted the progression of PC to highly metastatic and aggressive state.

Conclusions: Our findings suggest that ZNF507 is a novel key regulator of TGF-β signaling in the progression of malignant PC and could be a promising target for studying the development of advanced metastatic PCs.

Keywords: Prostate cancer, Metastasis, mCRPC, ZNF507, TGF-β signal
Background

The incidence of prostate cancer (PC) has become common and it remains the first men’s cause of cancer-related death in 56 countries [1, 2]. Androgen deprivation therapy (ADT) is widely used as a primary systemic therapy for primary stage PC, however, castration resistance ensues, which eventually leads to an androgen-independent metastatic castration-resistant PC (mCRPC) resulting in brain and bone metastasis [3–9]. These androgen-independent metastatic features of mCRPC can lead to the occurrence of neuroendocrine prostate carcinoma (NEPC), a highly aggressive form, which makes therapeutic options extremely limited [10–12]. Therefore, novel markers that efficiently predict disease progression are urgently needed for PC.

Zinc finger protein 507 (ZNF507) is an ancient, highly conserved C2H2-zinc finger protein, which is thought to regulate transcription [13]. Various studies have implicated ZNF507 as a risk factor for neurodevelopmental disorders and the early development [14–17]. Studies of genetic variations in cancer have indicated that ZNF507 may be relevant in several cancers [18–20]. However, the precise role of ZNF507 in the cancer remains unclear.

Transforming growth factor-β (TGF-β) signaling, which includes canonical and non-canonical pathways, has been linked with various cancers [21–23]. TGF-β plays a dual role in cancer progression: it exerts an inhibitory effect in the early stages of tumor development but promotes progression, migration, invasion, angiogenesis, and metastatic propagation in the later stages [24, 25]. In PC, TGF-β has been shown to provide an initiation signal for epithelial-mesenchymal transition (EMT), leading to the EMT-inducing transcriptional factors upregulation [26]. TGF-β also affects nuclear accumulation of the nuclear factor-kappa B (NF-κB), which leads to morphological changes in PC cells to the mesenchymal phenotype [27, 28]. Further, a study on NEPC reported TGF-β signaling promoted the invasiveness of PC cells, suggesting a strong link between TGF-β signaling and NEPC development [29–32]. Therefore, identifying regulators of TGF-β signaling in PC progression can help understand the development of highly aggressive PC.

In this study, we aimed to identify the ZNF507 function in PC and metastatic aggressive PC. We found that ZNF507 shows greater expression in the NE-like regions of PC and brain-metastasized PC cells. We demonstrate that ZNF507 upregulates genes for TGF-β signaling, including TGF-β receptor 1 (TGFBR1), mitogen-activated protein kinase 8 (MAP3K8), and the Paired Basic Amino Acid Cleaving Enzyme (FURIN). ZNF507 exacerbates the progression of PC, which results in aggressive metastatic features. Our findings suggest that ZNF507 is a regulator of TGF-β signaling in the progression of PC to malignancy, and shows potential for the attractive marker of advanced metastatic PC.

Methods

Patient samples

The PC tissue specimens were obtained from the Korea Biobank Network-KNUH, after obtaining the consent of the donors (KNUMC 2016-05-021). All experimental processes utilizing human tissues were performed at Daegu Gyeongbuk Institute of Science & Technology (DGIST) with IRB approval (DGIST-190,319-BR-006-02).

Cell culture

Human prostate RWPE1 cells were cultured in keratinocyte serum-free medium (K-SFM) (#17005-042, Gibco, Grand Island, USA). The human PC cell lines PC3, PC3M, and 22Rv1 were cultured in RPMI (SH30027, Hyclone, MA, USA), and DU145 cells were cultured in DMEM (SH30243, Hyclone). All cells were cultured in medium containing 10% fetal bovine serum (Hyclone) and 1% penicillin/streptomycin (Gibco).

Lentiviral transduction and cell transfection

pLKO.1-scramble and shZNF507 (Sigma, MO, USA) lentivirus containing supernatants were prepared through HEK293T mediated viral particle production. DU145 and 22Rv1 cells were treated with the lentivirus containing supernatants and 8 µg/ml polybrene (Sigma). After 48 h of incubation, the lentivirus-infected PC cells were selected by treatment with 1.5 µg/ml puromycin for 7 days (Invivogen, Hong Kong).

The pcDNA3.1 and pcDNA3.1-ZNF507 plasmid vectors were transfected to DU145 cells using Lipofectamine2000 (Thermo Fisher, MA, USA) following the manufacturer’s instruction. After 7 days of G418 (1.5 mg/ml, Sigma) selection, stable cell lines were established by confirming the ZNF507 expression. The same concentration of puromycin or G418 was treated every 3 days.

Cell proliferation assay

96-well seeded DU145 and 22Rv1 cells were treated with 10 µl of Cell Counting Kit-8 solution (CCK-8) (Dojindo, MD, USA) for 1 h before conducting the measurements. The plates were read at an optical density of 450 nm using a SpectraMaxiD3 spectrophotometer (Molecular Devices, CA, USA).

Proliferating cell nuclear antigen (PCNA) in DU145 and 22Rv1 cells were stained with primary antibody against PCNA (ab18197; Abcam, Cambridge, UK) followed by Alexa594 secondary antibody (A11037; Thermo Fisher) staining. DAPI-containing Vectashield
Fig. 1 (See legend on next page.)
Fluorochrome Dead-Cell-Apoptosis Kit with Annexin V-Alexa-488 & Propidium Iodide (PI) kit (Invitrogen) was used as per the manufacturer’s instructions. Data from cells was acquired by using the BD-Accuri-C6 flow cytometer (BD Biosciences), and 10,000 events per sample were acquired.

Quantitative reverse transcription PCR (qRT-PCR)

cDNA was synthesized from harvested RNA by using the MiniBEST Universal RNA extraction kit (cat#9767; Takara, Shiga, Japan), as per the manufacturer’s instructions. qRT-PCR analysis was conducted using the StepOnePlus RT-PCR system (Thermo Fisher) with TB Green Premix EX Taq (Takara). The relative mRNA expression of ZNF507 from benign hyperplasia (n = 6) and Gleason score 8 patient tissues (n = 15) specimens compared to its related β-actin intensity. The data are presented as the Means ± SD from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 versus normal control.

Immunoblot

Proteins from cell lysates or nuclear cytosol fractionized samples extracted by nuclear cytosol fractionization kit (Thermo Fisher) separated using 4–15 % or 4–20 % Mini-PROTEAN® TGX® Precast Protein Gels (Bio-rad) were transferred to nitrocellulose membranes, which were subsequently blocked for 2 h with 5 % skim milk or 5 % BSA. Primary antibodies (Table S2) diluted in the blocking solution were incubated overnight at 4°C. After thrice Tris-buffered saline with 0.05 % Tween-20 washing, and secondary antibodies incubation for 2 h at room temperature, the membrane was developed by using the Clarity Western ECL substrate (Bio-rad), and visualized using the ImageQuant LAS500 system (GE Healthcare, Uppsala, Sweden).

Dual-luciferase reporter assay

The human DNA sequences for the TGFBR1 promoter [-1378 to +75 bp (bp)], and the MAP3K8 promoter [-1441 to 0 bp] were cloned into the pGL3-basic vector. DU145 cells (1.5 × 10⁴ cells per well) in 96-well plates were co-transfected with the pGL3- control, pcDNA3.1, or the pcDNA3.1-ZNF507 plasmids. After 48 h, luciferase activity was measured using the SpectraMaxiD3 spectrophotometer (Molecular Devices). Firefly activity was normalized to renilla activity.
Fig. 2 (See legend on next page.)
Chromatin immunoprecipitation (ChIP)
ChIP assays were conducted using the EZ-Magna ChIP kit (Sigma) as per the manufacturer’s instructions. The following antibodies were used: ZNF507 (A303-274a; Bethyl Laboratories, TX, USA) and rabbit IgG (ab46540; Abcam). ChIP qRT-PCR analysis was performed on the purified DNA using four site-specific primer sets in the TGFBR1 promoter region (R1, -1541 to -1456 bp; R2, -1439 to -1298 bp; R3, -747 to -647 bp; R4, -396 to -309 bp) and three site-specific primer sets in the MAP3K8 promoter region (R1, -1405 to -1324 bp; R2, -1166 to -1079 bp; R3, -296 to -225 bp). The list of primers used in this study are described in Table S1.

Xenograft
All animal experiments were conducted with the permission and guidelines from the DGIST Laboratory Animal Resource Center. Five-week-old male BALB/c nude mice were subcutaneously injected with 200 µl PBS containing 6 × 10^6 scramble, shZNF507, pcDNA3.1, or pcDNA3.1-ZNF507 DU145 cells. The injections were administered to each side of the dorsal region. The tumor volume was calculated by the formula: tumor volume = length × width × width × 0.5. On the last day, the mice were sacrificed and the tumors were randomly excised for western blot or histological analysis.

In vivo metastasis analysis
Five-week-old male BALB/c nude mice were intravenously injected with 200 µl PBS containing 1 × 10^6 scrambled or shZNF507 treated DU145 cells. Five weeks after injection, lungs and livers of all mice were sampled for the histological analysis.

Immunohistochemistry and immunofluorescence
Samples of benign hyperplasia and PC patient and xenograft tumors were fixed in 10% formaldehyde, embedded in paraffin, and sectioned. Immunohistochemical staining of ZNF507 (ab85672; Abcam) was performed using the ZytolChemPlus HRP Kit (Zytomed, Berlin, Germany) as per the manufacturer’s instructions. For immunofluorescent staining, primary antibodies (Table S2) were incubated after 1% BSA in PBST blocking. Alexa488 (A11001; Thermofisher) and Alexa594 (A11037; Thermofisher) secondary antibodies were incubated for 2 h in a dark chamber followed by DAPI-containing Vectashield (Vector Laboratories) mounting.

Microarray and bioinformatics
GeneChip analysis was performed with scrambled shRNA or shZNF507 treated PC cells. Expression data was analyzed using ExDEGA (EBIOGEN Inc., Seoul, Korea), gene ontology (GO) analysis, and gene set enrichment analysis (GSEA). The related pathway analyses were performed using the Molecular Signature Database (MSigDB) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) database.

The expression profiles of ZNF507, TGFBR1, MAP3K8, and FURIN were analyzed using cancer datasets from various databases, including Gene Expression database of Normal and Tumor tissues (GENT2), The European Bioinformatics Institute (EMBL-EBI), Gene Expression Omnibus (GEO), cBioPortal for cancer genomics, and GEPIA.

Statistical analysis
All data were analyzed in triplicate from at least three independent experiments, and the results summarized as mean (SD). Mean differences were assessed by analysis of variance (ANOVA) using GraphPad Prism 5 (GraphPad, San Diego, CA, USA), and a p-value ≤ 0.05 was considered significant.
Fig. 3 (See legend on next page.)
Results

Elevated ZNF507 as a prognostic factor in highly graded PC patients

We first analyzed the ZNF507 expression in PC tissues using data from various databases. GENT2 and EMBL-EBI data analyses revealed significant ZNF507 upregulation in PC tissues (Fig. 1A, B). Interestingly, since there was no significant survival rate difference in prostate adenocarcinoma (PA) patients who showed high or low ZNF507 expression, considerably higher ZNF507 level was observed in recurrent PC tumors (Fig. 1C, D). Similarly, ZNF507 strongly expressed in high Gleason score PC in EMBL-EBI data (Fig. 1E). GEO database results showed increased ZNF507 in mCRPC tumors compared with that in normal or primary PC tissues (Fig. 1F). The PC type alteration frequency data in cBioPortal indicated the ZNF507 alteration frequency showed 14.81 % amplification in NEPC, 12.86 % amplification and 1.43 % mutation in mCRPC, and only 0.21 % amplification, 0.38 % mutation, and 0.178 % deletion in PA (Fig. 1G). To confirm our findings from the databases, we evaluated the ZNF507 expression in specimens from benign hyperplasia and high Gleason score (over 8) PC tissues and checked significantly elevated ZNF507 in aggressive PC tissues (Fig. 1H-J). As there was a remarkable increase in ZNF507 in mCRPC and an elevated alteration frequency for NEPC or mCRPC in the database, we examined the ZNF507 expression with the neuroendocrine marker NeuroD1 in benign hyperplasia and highly graded PC tissues. The results showed both ZNF507 and NeuroD1 were highly expressed in the malignant regions of the PC tissues (Fig. 1K, Fig.S1).

ZNF507 knockdown suppresses the growth, proliferation, and metastatic properties of PC cells

Next, we analyzed ZNF507 levels in human prostate and various PC cell lines. We selected two PC cell lines, DU145 and 22Rv1, displayed high ZNF507 expression (Fig.S2A, B). Following the ZNF507 knockdown, the shZNF507 #2 and #5 of both cell lines was selected based on their lowered mRNA and protein levels; the shZNF507 #5 (Fig. 2C) treated DU145 and 22Rv1 cells displayed nearly halved or lower ZNF507 expression, whereas those of the shZNF507 #2 (Fig.S3A) displayed nearly 30 % decrease in ZNF507 protein expression (Fig. 2A-C, Fig.S3A). We also confirmed that ZNF507 expressed in both nuclear and cytosolic area and knockdown of the gene was efficiently performed in both area (Fig.S2C, D). The knockdown of ZNF507 in PC cells induced a decrease in the proliferation rate (Fig. 2D, E). Further, colony formation ability was significantly repressed by the ZNF507 knockdown (Fig. 2F, G, Fig.S3C). The cell proliferative marker PCNA intensity was significantly reduced in the ZNF507 knockdown cells (Fig. 2H, Fig.S3B).

In the invasion and migration assay, decline in the migration and invasion ratio by ZNF507 knockdown in both PC cell lines were observed (Fig. 2I, J, Fig.S3D). We next confirmed the changes of epithelial-mesenchymal transition (EMT) markers, Twist1, Snail1, KLF8, and ZEB2 in DU145, and Slug, Snail, KLF8, and ZEB1 in 22Rv1 by ZNF507 knockdown (Fig. 2K, L). The anti-metastatic ZNF507 knockdown effect was checked by protein EMT markers expression; elevated E-cadherin and decreased N-cadherin, Vimentin, Snail, and Slug in both DU145 and 22Rv1 cells, indicating ZNF507 may affect the growth, proliferation, and metastatic properties of PC cells (Fig. 2M, Fig.S3E).

ZNF507 knockdown leads to cell cycle alteration and promotes apoptosis

As cell cycle is essential for proper cell proliferation [34], we examined cell cycle via flow cytometry. shZNF507 treated DU145 and 22Rv1 cells displayed significantly elevated G0/G1 phase cell population with decline in G2/M phase population, indicating the cell cycle phases length change by reduced ZNF507 (Fig. 3A, B, Fig.S3F). To further investigate the relevance, we examined the cell cycle checkpoint markers expression, CDK1, CDK2, CDK4, CDK6, CyclinA1, CyclinD1,
Fig. 4 (See legend on next page.)

Kwon et al. Journal of Experimental & Clinical Cancer Research (2021) 40:291
Page 9 of 17
CyclinE1, and CDC25A. As a result, the majority of the checkpoint markers were altered in both shZNF507 treated PC cell lines (Fig. 3C, D). Further, the protein expression of CyclinA1, CyclinB1, CyclinD1, CyclinE1, CDK2, and CDK4 was substantially diminished in shZNF507 treated PC cells, while there was no significant change in CDK6 (Fig. 3E, Fig.S3G).

Next, we evaluated the cell survival rate induced by ZNF507 knockdown using flow cytometry-based assays. We found that the ratio of early and late apoptosis was significantly increased in shZNF507 treated DU145 cells, and only early apoptosis was increased in shZNF507 treated 22Rv1 cells, with almost no detection of cells in late apoptosis in 22Rv1 cells (Fig. 3F, G, Fig.S3H). Interestingly, we found that the ratio of apoptotic population in DU145 and 22Rv1 was differently altered depending on the efficiency of ZNF507 knockdown. The association with increased apoptosis due to ZNF507 knockdown was confirmed from the elevated Bax, Survivin, cleaved-Caspase3, and cleaved-PARP, along with lowered Bcl-xL and Bcl-2 levels in shZNF507 treated PC cells (Fig. 3H, Fig.S3I). We next checked whether the changes in these factors were relevant in ZNF507 overexpression DU145 cells (Fig. 5G, Fig.S6). Taken together, we confirmed that the PC growth and proliferation change by ZNF507 knockdown were emerged with cell cycle stage length change and apoptotic death.

**ZNF507 knockdown reduces TGF-β signaling in PC cells**

To profile the related transcriptional changes underlying ZNF507 in PC, we performed a microarray. A total of 49 co-upregulated and 58 co-downregulated genes were profiled (Fig. 4A, B), and a GO based analysis revealed the several gene clusters enrichment related to various cancer properties, including angiogenesis, differentiation, migration, cell death, apoptotic process, and neurogenesis (Fig. 4C, D, Table S3). Considering its multiple tumor-promoting effects in various cancers [35], we focused on TGF-β signaling-related genes, namely TGFBR1, MAP3K8, and FURIN (Fig. 4A, red arrow). TGFBR1 encodes the TGF-β receptor 1 subunit of the receptor complex and plays a crucial role in downstream Smad-dependent canonical and Smad-independent non-canonical signaling [25, 26]. MAP3K8 is a mediator of the non-canonical TGF-β signaling pathway, proposed to be a proto-oncogene that activates the downstream MEK-ERK pathway in various cancers [36–38]. The FURIN is regulated by Smad-dependent canonical TGF-β signaling, and it is a proprotein convertase which plays a role in the cleavage of pro-TGF-β to its mature form, eventually stimulating the positive feedback loop of TGF-β signaling in cancers [39–41]. After confirming TGFBR1, MAP3K8, FURIN alteration by ZNF507 knockdown in PC cells (Fig. 4E-G, Fig.S4a), we examined the TGF-β downstream signals, and verified the diminished signal cascade activation (Fig. 4H, I, Fig.S4b, C). Expression of other several genes of GO analysis were confirmed by qRT-PCR in shZNF507 and ZNF507 overexpression cells (Fig.S5). A detailed explanation of TGF-β and its related signal pathway is provided in the schematic presented in Fig. 4.

**Upregulation of TGFBR1, MAP3K8, and FURIN by ZNF507 in PC**

To evaluate the relationship between ZNF507 and TGF-β signal factors, we conducted a correlation analysis using the GEPIA database. The spearman correlation (R) score between ZNF507 and TGFBR1 in PC was 0.76 (p < 0.001), indicating strong positive correlation (Fig. 5A). The score between ZNF507 and MAP3K8 (0.54, p < 0.001) and FURIN (0.64, p < 0.001) was also analyzed (Fig. 5B, C). To further determine this in our patient PC tissues, we assessed TGFBR1, MAP3K8, and FURIN levels and confirmed the elevated expression in the high Gleason scored PC tissues compared with benign hyperplasia tissues (Fig. 5D-F). We next checked whether the changes in these factors were relevant in
Fig. 5 (See legend on next page.)
ZNF507 overexpression DU145 cells (Fig. 5G, S6). We additionally investigated the transcriptional activity of TGFBR1 and MAP3K8 promoters regulated by ZNF507; since FURIN was already known to be regulated by Smad2/3 activation, we did not check its transcriptional activity [41]. We assessed the promoter activity of TGFBR1 and MAP3K8 by ZNF507 overexpression in DU145 cells and confirmed significant elevation of both genes (Fig. 5J, K). Furthermore, using ChIP qRT-PCR analysis with four site-specific primer sets of TGFBR1 and three primer sets of MAP3K8 promoter regions, based on released data of ZNF507 ChIP-seq on human MCF-7 cancer cells (NCBI, ENCSR4190DQ), we determined the putative ZNF507-binding region in the promoter of both genes (Fig. S7, Fig. 5H-M). This suggests ZNF507 is a potential transcriptional regulator of TGFBR1 and MAP3K8.

ZNF507 depletion suppresses tumor growth and metastasis in vivo and attenuates NEPC-like phenotype by TGF-β signaling inhibition

To validate the promoting effect of ZNF507 in PC progression, we conducted an in vivo DU145 xenograft (the 22Rv1 was excluded due to its slow growth rate). The growth rate, volume, and weight of the ZNF507 knockdown xenografted tumors declined significantly, while ZNF507 OE tumors increased in faster rate (Fig. 6A-C, Fig. S8A, Fig. S11A, B). Fluorescent staining of tumors showed relatively elevated Ki67 levels with lowered cleaved-Caspase3 expression in scramble xenografted tumors compared to ZNF507 knockdown xenografted tumors (Fig. S8B). Further, we detected intensified expression pattern for ZNF507, TGFBR1, MAP3K8, and FURIN in the scramble xenografted tumors (Fig. 6D, Fig. S8C). We additionally confirmed the altered activation of the downstream TGF-β signaling cascade (Fig. 6E-G, Fig. S8D-F, Fig. S11C-E). In the analogous staining of the neuroendocrine markers, NeuroD1 and Synaptophysin, we detected a pattern similar to that of ZNF507 and TGF-β cascades (Fig. 59, Fig. S11F). This was consistent with the staining pattern of ZNF507 overexpression cells (Fig. S10). Finally, we conducted in vivo metastasis analysis, and identified the ZNF507 knockdown remarkably suppressed the metastasis of DU145 cells in the lung and liver with the decrease of TGFBR1, MAP3K8, and FURIN (Fig. 6H, I).

Discussion

Since castration-resistant metastatic features remain a major obstacle for PC treatment, identifying novel marker for metastatic aggressive PC is essential for improving PC treatment [3, 6, 42]. In the current study, we identified the biological significance of ZNF507 in the progression of PC to aggressive phenotype by regulating TGF-β signaling (Fig. 6 H). The data retrieved from PC databases indicated prominent ZNF507 expression in high-grade PCs. Our findings on ZNF507 pattern are consistent with ZNF507 expression data in Fig. S2: higher ZNF507 in DU145 and 22Rv1 cells, which were derived from brain-metastatic cells (DU145) and propagated xenograft after castration-induced regression (22Rv1) [43, 44]. As the ZNF507 expression was lowered in bone metastatic PC cell line PC3M (Fig. S2B), it is speculated ZNF507 dominantly functions in ectodermal regulation than mesodermal control. As DU145 is expresses the NE marker NeuroD1 and its transcription is regulated by the canonical TGF-β signaling mediator Smad3 [45, 46], it is plausible that ZNF507 functions in PC progression to the NE-like phenotype. Accumulating evidence suggests TGF-β
Fig. 6 (See legend on next page.)
signaling is involved in the development of PC or high-grade mCRPC through cancer cell cycle progression, EMT, and metastasis [29, 31, 47–49]. Our in vivo experimental studies, which displayed alteration of tumor growth and metastatic capacity affected by ZNF507 knockdown, also support this hypothesis (Fig. 6, Fig.S8, Fig.S9, Fig.S11). As there was a limitation of in vivo metastasis models that injecting tumor cells intravenously does not perfectly recapitulate the metastatic cascade, they were sufficient to prove the physiological changes in cancer properties by ZNF507 knockdown. Therefore, it is worth paying attention to ZNF507 as an attractive marker for aggressive high-grade PC.

The crosstalk between adenocarcinoma and NE-like PC and the underlying PC transformation to the NE-phenotype mechanism is complicated [50, 51]. Several studies have shown a link between NEPC and cell lineage plasticity, NE trans-differentiation, and regression to stemness by numerous factors [51–56]. Of these, the TGF-β signaling has been consistently linked with the NE-differentiation and EMT in NE-like cancers [57, 58]. It affects the NEPC progression, contributing neurogenesis, neural differentiation, and CNS development through diverse pathways [59–62]. Our current results indicate that ZNF507 may influence the extracellular matrix, embryonic differentiation, neurodevelopment, and immune response (Fig. 4). Reports about ZNF507 alteration during neurodevelopment also support our findings [16, 17]. Similar to ZNF507 [14, 15], TGF-β and its related immune activity has been linked to schizophrenia, suggesting an interaction in neurodevelopmental disorders [63, 64]. For these reasons, in addition to further studying ZNF507 gene in other cancers, studies on ZNF507 and TGF-β signaling in early and neurodevelopment are highly recommended. As such, several projects are currently underway that investigate the correlation in early development, neurogenesis, and the ZNF507.

Conclusions
In conclusion, we demonstrated the pivotal ZNF507 effect in promoting PC progression to the aggressive state. We propose that ZNF507 contributes to the positive feedback loop in TGF-β signaling by regulating TGFBR1 and MAP3K8 activation for the progression of PC to the metastatic aggressive state, and this finding highlights its potential as a promising marker for the diagnosis of metastatic PC and high-grade mCRPC or NEPC (Fig. 6).

Abbreviations
ADT: Androgen deprivation therapy; mCRPC: Metastatic castration-resistant prostate cancer; NEPC: Neuroendocrine prostate carcinoma; PA: Prostate adenocarcinoma; EMT: Epithelial-mesenchymal transition; GO: Gene ontology; GSEA: Gene set enrichment analysis; MSigDB: Molecular Signature Database; KEGG: Kyoto Encyclopedia of Genes and Genome; GENT: Gene Expression database of Normal and Tumor tissues; EMBL-EBI: The European Bioinformatics Institute; GEO: Gene Expression Omnibus

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13046-021-02094-3.
expression of ZNF507 in RWPE1, DU145, PC3, PC3M, and 22Rv1 cell lines measured by qRT-PCR. The data are presented as the Means ± SD from three independent experiments. *p < 0.05, **p < 0.01 versus RWPE1 cells as a control. (B) Representative images of protein expression data of ZNF507 in the RWPE1, DU145, PC3, PC3M, and 22Rv1 cell lines analyzed by western blot. β-actin was used as a normalization control. Three independent experiments per each target were performed. (C) Representative images of protein expression data of ZNF507 in RWPE1, DU145, PC3, PC3M, and 22Rv1 cell lines performed by immunocytochemistry. (Scale bar = 50 μm). The graph below presents relative corrected total cell fluorescence (CTCF). At least 4 pictures from each sample were taken and the CTCF were calculated. (D) Colony formation of the shZNF507 treated DU145 or 22Rv1 cells. LaminB1 was used as a normalization control for nuclear samples and β-tubulin was used as a normalization control for cytosol samples. Three independent experiments per each target were performed. (D) Representative images of fluorescent imaging stained with DAPI (blue), PI (red), and β-actin was used as an endogenous normalization control. The data are presented as the Means ± SD from three independent experiments.

**Supplemental Figure 3.** (A) Representative protein expression data assessed by western blot for ZNF507 in scramble or shZNF507 DU145 or 22Rv1 cells, the lines selected from the qRT-PCR assessment of ZNF507 knockdown; shZNF507 #2 treated DU145 and 22Rv1 cells. (B) PCNA staining of the scramble or shZNF507 DU145 or 22Rv1 cells performed by immunocytochemistry. (Scale bar = 50 μm). The graph below presents colony number and relative diameter. Each experiment consists of four samples from the same group of cells were measured and the three independent experiments were conducted. (D) Representative images of the invasion and migration assay performed with the scramble or shZNF507 DU145 or 22Rv1 cells using trans-well plate (Scale bar = 50 μm). The graph below presents relative ratio of migration and invasion from the transwell migration and invasion assay. At least four pictures from each sample were taken and the three independent experiments were performed. (E) Representative images of protein expression data of E-cadherin, N-cadherin, Vimentin, Snail, and Slug in the scramble or shZNF507 DU145 or 22Rv1 cells assessed by western blot. β-actin was used as an endogenous control. (F) Cell cycle analysis was performed with scramble or shZNF507 DU145 or 22Rv1 cells by propidium iodide (PI) staining. The proportion of cells in each cycle was measured. The graph in the right panel indicates ratio of cell cycle population from cell cycle analysis. Three independent experiments were performed and at least four samples per group were measured in each experiment. (G) Representative images of protein expression data of CyclinA1, CyclinB1, CyclinD1, CyclinE1, CDK2, CDK4, and CDK6 in the scramble or shZNF507 DU145 or 22Rv1 cells assessed by western blot. β-actin was used as an endogenous control. (H) Apoptosis analysis conducted by PI-Annexin V-FITC staining in the mock and shZNF507 DU145 cells. The graph in the right panel presents cell cycle population from the apoptosis analysis. Three independent experiments were performed and at least four samples per group were measured in each experiment. (I) Representative images of protein expression data of NeuroD1 and Synaptophysin assessed by western blot in the mock and shZNF507 DU145 cells. (J) Colony formation of the mock and shZNF507 DU145 cells assessed by soft agar assay. The graph below indicates the number and diameter of the colonies. (C) Colony formation of the mock and shZNF507 OE DU145 cells performed by soft agar assay. The proportion of cells in each cycle was calculated. The graph in the right panel presents the ratio of cell cycle population. Three independent experiments were performed and at least four samples per group were measured in each experiment. (F) Representative images of the migration and invasion assay performed with the mock or ZNF507 OE DU145 cells using trans-well plate (Scale bar = 50 μm). The graphs below present relative ratio of migration and invasion of the data from the migration and invasion assay. At least 4 pictures from each sample were taken and the three independent experiments were performed. (G) Representative images of protein expression data of E-cadherin, N-cadherin, Vimentin, Snail, and Slug in the scramble or shZNF507 DU145 or 22Rv1 cells assessed by western blot. β-actin was used as an endogenous control. The data are presented as the Means ± SD from three independent experiments.

**Supplemental Figure 4.** (A) Representative images of the protein expression data of TGF-β1, MAP3K8, and FURIN detected by western blot in the scramble and shZNF507 DU145 or 22Rv1 cells, the lines selected from the qRT-PCR assessment of ZNF507 knockdown; shZNF507 #2 treated DU145 and 22Rv1 cells. (B) Representative images of protein expression data of canonical TGF-β signal proteins, Smad2, and Smad3 with their phosphorylated forms, assessed by western blot. β-actin was used as a normalization control. (C) Representative images of the protein expression data of non-canonical TGF-β signal proteins, RAS, MEK, phosphorylated-MEK, ERK, and phosphorylated-ERK, examined by western blot. β-actin was used as a normalization control. Three independent experiments per each target were performed. (D) Representative images of the protein expression data of NeuroD1 (green) expression assessed by immunofluorescence in the scramble and shZNF507 xenografted tumors (Scale bar = 100 μm, blue: DAPI staining). (E) Representative protein expression data of NeuroD1 and Synaptophysin assessed by western blot in the scramble and shZNF507 xenografted tumors. β-actin was used as a normalization control. For all the data, three independent experiments were conducted. (F) Representative images of the protein expression data of NeuroD1 and Synaptophysin assessed by western blot in the scramble and shZNF507 xenografted tumors. β-actin was used as a normalization control. For all the data, three independent experiments were conducted.
The authors declare no conflicts of interest.

Acknowledgements
Not applicable.

Authors’ contributions
KW, CSK, RZY, PS designed the study. KW, KD, KHG, PJK, HJE, CGJ, YS, YW, PS administered the experiments. KW, KHG, YW, HSH, CDH, YJK, KMO investigated the data. HY, LJN, KTG contributed human patient samples and IHC evaluation. KW, PS, and CSK wrote the manuscript. The final data and manuscript have been discussed and approved by all authors.

Funding
This research was supported by the P-CoE program of DGIST (DGIST 20-CoE-BT-01) and the Basic Research Program through the National Research Foundation of Korea (NRF) funded by the MSIT (2020R1A4A1018280).

Availability of data and materials
All data supporting the conclusions of this article are included in the manuscript and supplementary information files.

Declarations
Ethics approval and consent to participate
The patient tissue specimens were obtained from the Korea Biobank Network-KNUH, after obtaining the consent of the donors (KNUMC 2016-05-021). All experimental processes utilizing human tissues were performed at Daegu Gyeongbuk Institute of Science & Technology (DGIST) with IRB approval (DGIST-190319-BR-006-02). All animal experiments were conducted with the permission and guidelines from the DGIST Laboratory Animal Resource Center.

Consent for publication
All subjects have written informed consent.

Competing interests
The authors declare no conflicts of interest.

Author details
1Core Protein Resources Center, DGIST, Daegu, Republic of Korea. 2Division of Biotechnology, DGIST, Daegu, Republic of Korea. 3School of Life Science, BK21 FOUR KNU Creative Bioscience, Kyungpook National University, Daegu, Korea. 4College of Veterinary Medicine, Kyungpook National University, 41566 Daegu, Korea. 5Department of Brain and Cognitive Sciences, DGIST, Daegu, Republic of Korea. 6School of Media Communication, Hanyang University, Wangsimni-ro 222, Seongdong-gu, Seoul, South Korea. 7Department of News-team, SBS (Seoul Broadcasting System), Mokdongseo-ro 161, Yangcheon-gu, Seoul, South Korea. 8Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea. 9Brain Science and Engineering Institute, Kyungpook National University, 41566 Daegu, Republic of Korea. 10Gyeongsangbuk-do Livestock Research institute, Yeongju, South Korea. 11Department of Animal Science and Biotechnology, ITRD, Kyungpook National University, 37224 Sangju, Republic of Korea.

Received: 30 March 2021 Accepted: 3 September 2021
Published online: 18 September 2021

References
1. Global Burden of Disease. Cancer C, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease study. JAMA Oncol. 2019;5:1749–68.
2. Van Hemelrijck M, Folkvall J, Adfors T, Akre O, Holmberg L, Garro H, et al. Causes of death in men with localized prostate cancer: a nationwide, population-based study. BJU Int. 2016;117:507–14.
3. Teo MY, Rinthikph DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:749–99.
4. Zhang Q, Yin X, Pan Z, Cao Y, Han S, Gao G, et al. Identification of potential diagnostic and prognostic biomarkers for prostate cancer. Oncol Lett. 2019;18:4237–45.
5. Seisen T, Roupert M, Gomez F, Malouf GG, Shariat SF, Peyronnet B, et al. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. Cancer Treat Rev. 2016;48:25–53.
6. Ku SY, Gleave ME, Beltran H. Towards precision oncology in advanced prostate cancer. Nat Rev Urol. 2019;16:645–54.
7. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 2004;351:1488–90.
8. Liang W, Wang F, Chen Q, Dai J, Escara-Wilke J, Keller ET, et al. Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone. J Cancer Res Clin Oncol. 2019;145:1999–2012.
9. Ryan C, Wefel JS, Morgans AK. A review of prostate cancer treatment impact on the CNS and cognitive function. Prostate Cancer Prostatic Dis. 2020;23:207–19.
10. Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Ann J Surg Pathol. 2014;38:556–67.
11. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate. 1999;39:135–48.
12. Hansson J, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Scand J Urol Nephrol Suppl. 2003;212:228–36.
13. Liu H, Chang LH, Sun Y, Lu X, Stubbs L. Deep vertebrate roots for mammalian zinc finger transcription factor subfamilies. Genome Biol Evol. 2014;6:510–25.
14. Talsukovski MD, Rosenfeld JA, Blumenthal I, Pillalamarri V, Chiang C, Heilbut A, et al. Sequencing chromosomal abnormalities reveals neurendodevelopmental loci that confer risk across diagnostic boundaries. Cell. 2012;149:525–37.
15. Curtis D, Consortium UK. Practical Experience of the application of a weighted burden test to whole exome sequence data for obesity and schizophrenia. Ann Hum Genet. 2016;80:38–49.
16. Zhang W, Li Q, Deyssenroth M, Lambertini L, Fink J, Harm J, et al. Timing of prenatal exposure to trauma and altered placental expressions of hypothalamic-pituitary-adrenal axis genes and genes driving neurodevelopment. J Neuroendocrinol. 2018;30:e12581.
17. Zhang W, Harm J, Li Q, Deyssenroth MA, Lambertini L, Huang Y, et al. Moderate prenatal stress may buffer the impact of Superstorm Sandy on placental genes. Stress in Pregnancy (SIP) Study. PLoS One. 2020;15(10):e026605.
18. Van den Broeck T, Joniau S, Castronovo V, Turtoi A. Stromal Modulators of TGF-beta in Cancer. J Clin Med. 2017;6:7.

Figure S11. (A) Tumors extracted from the xenograft experiments conducted with the mock and ZNF507 OE DU145 cells. B-actin was used as a normalization control. Supplemental Figure S11. (A) Tumors extracted from the xenograft experiments conducted with the mock and ZNF507 OE DU145 cells injected into BALB/C nude mice. Six mice were performed for experiment and three tumors were used for Western blot, while other three tumors were used for histological analysis. (B) Graph showing the average weight of the mock and ZNF507 OE DU145 xenografted tumors. (C) Representative western blot data of ZNF507, TGFB1, MAP3K8, and FURIN expression in the mock and ZNF507 OE DU145 xenografted tumors. (D) Representative western blot data of RAS, p-MEK, MEK, p-ERK, and ERK expression in the mock and ZNF507 OE DU145 xenografted tumors. (E) Representative images of p-Smad2, Smad2, p-Smad3, and Smad3 in in the mock and ZNF507 OE DU145 xenografted tumor assessed by western blot. (F) Representative western blot data of NeuroD1 and Synaptophysin expression in the mock and ZNF507 OE DU145 xenografted tumors. For all the western blot, β-actin was used as a normalization control and three independent experiments were performed.
24. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol. 2012;13: 616–30.

25. French R, Feng Y, Paulkin S. Targeting TGFbeta Signalling in Cancer: Toward Context-Specific Strategies. Trends Cancer. 2020;6(5):538–40.

26. Jiang WQ, Sanders AJ, Katchi M, Ungefroren H, Gieseler F, Prince M, et al. Tissue invasion and metastasis: molecular, biological and clinical perspectives. Semin Cancer Biol. 2015;35(Supplement):5244–75.

27. Nguyen DP, Li J, Yadav SS, Tewari AK. Recent insights into NF-kappaB signalling pathways and the link between inflammation and prostate cancer. BJU Int. 2014;114:168–76.

28. Zhang Q, Helfand BT, Jiang TL, Zhu L, Chen L, Yang XJ, et al. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res. 2009;15:3557–67.

29. Akamatsu S, Wyatt AW, Lin D, Lytowski S, Zhang F, Kim S, et al. The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Rep. 2015;12:922–36.

30. Redman JM, Steinberg SM, Gulley JL. Quick efficacy seeking trial (QuEST): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer. J Immunother Cancer. 2018;6:91.

31. Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, et al. Dominant-negating TGF-beta Receptor Enhances PSA-Marked Human T Cell Proliferation And Augments Prostate Cancer Eradication. Mol. Cell. 2018;78:1855–66.

32. Liu Q, Tong D, Liu G, Yu J, Do K, Geary K, et al. Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-beta1/STAT3 axis-regulated EMT. Cell Death Dis. 2017;8:e3007.

33. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;4:402–8.

34. Golias CH, Charalabopoulos A, Charalabopoulos K. Cell proliferation and cell cycle control: a mini review. Int J Clin Pract. 2004;58:1134–41.

35. Kuonen F, Secondini C, Ruegg C. Molecular pathways: emerging pathways mediating growth, invasion, and metastasis of tumors progressing in an irradiated microenvironment. Clin Cancer Res. 2012;18:1596–202.

36. Vougioukalaki M, Kanellis DC, Gkouskou K, Eliopoulos AG. Tpl2 kinase signal transduction in inflammation and cancer. Cancer Lett. 2011;304:80–9.

37. Lee HJ, Lee JH, Lee SH, Do SI, Cho SD, Forslund O, et al. TPL2 is an oncogenic driver in keratoacanthoma and squamous cell carcinoma. Cancer Res. 2016;76:6712–22.

38. Christoforidou AV, Papadaki HA, Margioris AN, Eliopoulos GD, Tsatsanis C. Expression of the Tpl2/Cot oncogene in human T-cell neoplasias. Mol. Cancer. 2004;3:29.

39. Jaaks P, Bernasconi M. The protein convertase furin in tumour progression. Int J Cancer. 2017;141:654–63.

40. Hagihara S, Murakumo Y, Mii S, Shigetomi T, Yamamoto N, Furue H, et al. Processing of CD109 by furin and its role in the regulation of TGF-beta signaling. Oncogene. 2010;29:2181–91.

41. Chang HM, Cheng JC, Klauser C, Leung PC. Recombinant BMP4 and BMP7 increase activin A production by up-regulating inhibin beta A subunit and furin expression in human granulosa-lutein cells. J Clin Endocrinol Metab. 2015;100:E375–86.

42. Galletti G, Leach BJ, Lam L, Tagawa ST. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treat Rev. 2017;57:16–27.

43. Sramkoski RM, Pretlow TG 2nd, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim. 1999;35:403–9.

44. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer. 1979;21:274–81.

45. Osborne JK, Larsen JE, Gonzales JS, Shames DS, Sato M, Wistuba II, et al. NeuroD1 regulation of migration accompanies the differential sensitivity of human prostate carcinoma cell line (DU 145). Int J Cancer. 1978;21:274–81.

46. Al Shareef Z, Kardooni H, Murillo-Garzon V, Domenici G, Stylianakis E, Steel JH, et al. Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1. Oncogene. 2018;37:5330–34.

47. Fine SW. Neuroendocrine tumors of the prostate. Mod Pathol. 2018;31:122–32.

48. Liu X, Chen L, Fan Y, Hong Y, Yang X, Li Y, et al. IFITM3 promotes bone metastasis of prostate cancer cells by mediating activation of the TGF-beta signaling pathway. Cell Death Dis. 2019;10:517.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.